Primary indication(s): Invasive Aspergillus infections (including CNS aspergillosis)
Candida infections both mucocutaneous and invasive - i.e. Candidemia.
Antifungal prophylaxis in immunocompromised patients.
Therapeutic drug monitoring recommended to ensure adequate concentrations and exclude toxicity (Discuss with ID). -Target 1 – 5.5 μg/mL, 5-7 days after starting therapy
QTc interval in patients at elevated risk.
Monitor hepatic profile.
CYP450 interactions ++
Other QTc prolonging agents
Recommend review of pt medications due to high frequency of significant interactions
Antimicrobial class: Triazole antifungal, Second generation
Pregnancy category: D
Urine penetration: Poor
Lung penetration: Therapeutic
CSF penetration: Therapeutic
Antimicrobials
